With the American Heart Association (AHA) and American Stroke Association (ASA) updating their guidelines for preventing strokes, experts now say that Ozempic and other GLP-1 drugs may reduce stroke ...
The American Stroke Association just released new stroke prevention guidelines. They include considering GLP-1 receptor agonists. Doctors applaud the new guidance. More than 795,000 people in the U.S.
Recent updates from the American Stroke Association reveal groundbreaking strategies for preventing strokes, which affect nearly 800,000 Americans annually. The latest guidelines underscore an ...
The Healthy @Reader's Digest on MSN
This is the most effective way to prevent stroke death, expert doctor says
Up to 80% of first-time strokes are preventable, says the American Stroke Association. New guidelines offer a better look at risk factors, including special considerations for women.
Please provide your email address to receive an email when new articles are posted on . In the OCEANIC-STROKE trial, asundexian met the primary efficacy and safety endpoints for secondary prevention ...
Early dual antiplatelet therapy shows superior efficacy in reducing stroke recurrence compared with aspirin monotherapy.
The American Stroke Association (ASA) has issued an updated guideline for primary stroke prevention. The first update in a decade, the 2024 Guideline for the Primary Prevention of Stroke, replaces the ...
Experts this week identified new risks and issued updated recommendations for preventing strokes, a leading cause of death and disability in the U.S. It's the first time in a decade that health ...
Please provide your email address to receive an email when new articles are posted on . A new guideline on prevention of a first stroke calls for more screening of risk factors in primary care ...
Nearly 25 years ago, Joseph P. Broderick, MD, stroke expert and neurologist at the University of Cincinnati in Cincinnati, reflected on what stroke prevention and management might be like in 2025. At ...
New data reveal how Bayer's asundexian failed to prevent strokes, imperiling $5.5B blockbuster hopes
Bayer suspended the phase 3 trial for its factor XIa inhibitor asundexian late last year after the drug showed “inferior efficacy” at preventing strokes in patients with atrial fibrillation compared ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results